Abstract
We have evaluated a two-tier neonatal cystic fibrosis (CF) screening of immunoreactive trypsinogen (IRT) followed by CFTR gene mutation analysis using a systematic scanning of exons 7, 10, and 11, and, if necessary, by direct DNA sequencing. Over an 18-month period we screened 32,300 neonates born in the western part of Britanny. The first tier, involving IRT screening at 3 days of age, utilizes a low elevation of the trypsinogen level (600 ng/ml), which is highly sensitive. The second tier, which corresponds to the exhaustive screening for mutations in three exons of the gene, is highly specific for this population (Britanny). The false positive rate is very low, and no false negatives have been reported to date. This strategy has allowed the identification of five novel alleles (V322A, V317A, 1806 del A, R553G, G544S). Moreover the test can be adapted to other countries in which the distribution of mutations is established.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anguiano A, Oates RD, Amos JA, Dean M, Gerrard B, Stewart C, Maher TA, White MB, Milunsky A (1992) Congenital bilateral absence of the vas deferens: a primarily genital form of cystic fibrosis. JAMA 267:1794–1797
Applegarth DA, Davidson AGF, Kirby LT (1979) Dried blood spot screening for cystic fibrosis. Lancet II:1936–1937
Audrézet MP, Mercier B, Guillermit H, Quéré I, Verlingue C, Rault G, Férec C (1993a) Identification of 12 novel mutations in the CFTR gene. Hum Mol Genet 2:51–54
Audrézet MP, Costes B, Ghanem N, Fanen P, Verlingue C, Morin JF, Mercier B, Goossens M, Férec C (1993b) Screening for cystic fibrosis in dried blood spots of newborns. Mol Cell Probes 7:497–502
Boat TF, Welsh MJ, Beaudet AL (1989) In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic basis of inherited disease. McGraw Hill, New York, pp 2649–2680
Crossley JR, Elliott RB, Smith PA (1979) Dried-blood spot screening for cystic fibrosis in the newborn. Lancet 1979; I:472–474
Dumur V, Gervais R, Rigot JM, Lafitte JJ, Manouvrier S, Biserte J, Mazeman E, Roussel P (1990) Abnormal distribution of CF ΔF508 allele in azoospermic men with congenital aplasia of the epididymis and vas deferens. Lancet 336:512
Fanen P, Ghanem N, Vidaud M, Besmond C, Martin J, Costes P, Plassa F, Goossens M (1992) Molecular characterization of cystic fibrosis: 16 novel mutations identified by analysis of the whole cystic fibrosis transmembrane conductance regulator (CFTR) coding regions and splice site junctions. Genomics 13:770–776
Feingold J, Hennequet A, Jéhanne M, Feigelson J, Toudic L, Quiniou O, Briard ML (1974) Fréquence de la fibrose kystique du pancréas en France. Ann Génét 17:257–259
Férec C, Audrézet MP, Mercier B, Guillermit H, Moullier P, Quéré I, Verlingue C (1992) Detection of over 98% cystic fibrosis mutations in a Celtic population. Nat Genet 1:188–191
Férec C, Verlingue C, Guillermit H, Quéré I, Raguénès O, Feigelson J, Audrézet MP, Moullier P, Mercier B (1993) Genotype analysis of adult cystic fibrosis patients. Hum Mol Genet 2:1557–1560
Gregg RG, Wilfond BS, Farrell PM, Laxova A, Hassemer D, Mischler EH (1993) Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis (CF): comparison of screening protocols. Am J Hum Genet 52:616–626
Gyllensten UB, Erlich HA (1988) Generation of single-stranded DNA by the polymerase chain reaction and its application to direct sequencing of the HLA-DQA locus. Proc Natl Acad Sci USA 85:7652–7656
Hammond KB, Abman SH, Sokol RJ, Accurso FJ (1991) Efficacy of statewide neonatal screening for cystic fibrosis by assay of trypsinogen concentrations. N Engl J Med 325:769–774
Heeley ME, Keenan CA, Heeley AF (1991) An update of cystic fibrosis screening in East Anglia. Pediatr Pulmonol 7 [Suppl]:90
Iovanna JL, Keim V, Nordback I, Montalto G, Camarena J, Letoublon C, Levy P, Berthézène P, Dagorn JC (1994a) Serum levels of pancreatitis-associated protein as indicator of the course of acute pancreatitis. Gastroenterology 106:728–734
Iovanna JL, Férec C, Sarles J, Dagorn JC (1994b) The pancreatitisassociated protein (PAP): a new candidate for neonatal screening of cystic fibrosis. CR Acad Sci III 317:561–564
Kerem BS, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui LC (1989) Identification of the cystic fibrosis gene: genetic analysis. Science 245:1073–1080
King DN, Heeley AF, Walsh MP, Kuzemko JA (1979) Sensitive trypsin assay for dried blood specimens as a screening procedure for early detection of cystic fibrosis. Lancet II:1217–1219
Kristidis P, Bozon D, Corey M, Markiewicz D, Rommens J, Tsui LC, Durie P (1992) Genetic determination of exocrine pancreactic function in cystic fibrosis. Am J Hum Genet 50:1178–1184
Mercier B, Lissens W, Audrézet MP, Bonduelle M, Liebaers I, Férec C (1993) Detection of more than 94% cystic fibrosis mutations in a sample of Belgian population and identification of four novel mutations. Hum Mutat 2:16–20
Mercier B, Verlingue C, Lissens W, Silber F, Novelli G, Bonduelle M, Audrézet MP, Férec C (1995) Is congenital bilateral absence of vas deferens a primary form of cystic fibrosis? Analyses of the CFTR gene in 67 CBAVD patients. Am J Hum Genet 56:272–277
Ranieri E, Lewis BD, Gerace RL, Ryall RG, Morris CP, Nelson PV, Carey WF, Robertson EF (1994). Neonatal screening for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis: four years' experience. BMJ 308:1469–1472
Riordan JR, Rommens JM, Kerem BS, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL, Drumm ML, Iannuzzi MC, Collins FS, Tsui LC (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245:1066–1073
Rommens JM, Iannuzzi MC, Kerem BS, Drumm ML, Melmer G, Dean M, Rozmahel R, Cole JL, Kennedy D, Hidaka N, Zsiga M, Buchwald M, Riordan JR, Tsui LC, Collins FS (1989) Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245:1059–1064
Sanger F, Nickler S, Coulson AR (1977) DNA sequencing with chain terminating inhibitors. Proc Natl Acad Sci USA 74:5463–5467
Seltzer WK, Accurso F, Fall MZ, VanRiper AJ, Descartes M, Huang Y, McCabe ERB (1991) Screening for cystic fibrosis: feasibility of molecular genetic analysis of dried blood specimens. Biochem Med Metab Biol 46:105–109
Travert G, Duhamel JF (1983) Dépistage néonatal systématique de la mucoviscidose par dosage de la trypsine immunoréactive: bilan de 80 000 tests. Arch Fr Pediatr 40:95–98
Verlingue C, Kapranov NI, Mercier B, Ginter EK, Petrova NV, Audrézet MP, Férec C (1994) Complete screening of mutations in the coding sequence of the CFTR gene in a sample of CF patients from Russia: identification of three novel alleles. Hum Mutat n
Wilcken B (1993) Newborn screening for cystic fibrosis: its evolution and a review of the current situation. Screening 2:43–62
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Férec, C., Verlingue, C., Parent, P. et al. Neonatal screening for cystic fibrosis: result of a pilot study using both immunoreactive trypsinogen and cystic fibrosis gene mutation analyses. Hum Genet 96, 542–548 (1995). https://doi.org/10.1007/BF00197409
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00197409